Glenmark molecule to enter human trials in Netherlands

18 Feb 2011 Evaluate

Glenmark Pharmaceuticals has filed an application in Netherlands for human trials on its molecule ‘GRC 17536’, which aims to treat pain and respiratory disorders. The company has completed animal trials on its novel chemical entity (NCE) GRC 17536 and has filed the Phase I application for first-in-man trial in Netherlands, Glenmark Pharmaceuticals.

The total market for asthma and chronic lung disease is about $30 billion and for osteoarthritis and neuropathic pain, it is nearly $10 billion. There is a huge unmet medical need in both therapeutic areas globally. crackcrack

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×